News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III (World)
Dermira (DERM) Release: Second CIMZIA (Certolizumab Pegol) Phase III Trial Meets Co-Primary Efficacy Endpoints In Patients With Moderate-To-Severe Chronic Plaque Psoriasis 12/8/2016
Regeneron (REGN) And Sanofi (SNY)i Announce Marketing Authorization Application For Dupixent (Dupilumab) Accepted For Review By The EMA 12/8/2016
Horizon Pharma (HZNP) Craters as Rare Neuromuscular Drug Flunks Late-Stage Study 12/8/2016
Valeant (VRX) Announces Phase 3 Results For Psoriasis Treatment IDP-118 12/8/2016
Otsuka Pharmaceutical Development & Commercialization, Inc. And H. Lundbeck A/S (LUN.CO) Present Data At ACNP Annual Meeting On Long-Acting Injectable Aripiprazole As A Potential Maintenance Treatment For Bipolar I Disorder 12/7/2016
China-Prevalent Form Of NSCLC Responds To AstraZeneca PLC (AZN) Drug 12/7/2016
Auris Med (EARS) On Track To Resume Enrollment Of Keyzilen Tinnitus Program Following Regulatory Feedback 12/6/2016
Celgene (CELG) Release: ABOUND Data Presented At The World Conference On Lung Cancer Further Explores Safety And Efficacy Of ABRAXANE For Challenging Patient Populations 12/6/2016
Theravance Biopharma (TBPH) Highlights Filing Of EU Regulatory Submission For The Closed Triple In COPD By GlaxoSmithKline (GSK) And Innoviva 12/5/2016
GW Pharma (GWPH) Announces New Epidiolex® (CBD) Positive Phase III Data In Dravet Syndrome And Lennox-Gastaut Syndrome 12/5/2016
NeuroDerm (NDRM) to Discontinue ND0612H Phase III, Suspend iNDiGO After FDA Meeting 12/5/2016
GW Pharma (GWPH) Announces Epidiolex (Cannabidiol) Data Presentations And Educational Programs At The American Society Of Epilepsy Annual Meeting 12/1/2016
Jazz Pharma (JAZZ) Announces That Patient Enrollment Is Complete For The Phase 3 Study Of JZP-110 Evaluating Excessive Sleepiness In Narcolepsy 11/29/2016
Santen Pharma Announces Phase III SAKURA Program Topline Results In Patients With Non-Infectious Uveitis Of The Posterior Segment 11/28/2016
Intec Pharma Enters Into Agreement With The Michael J. Fox Foundation Around Its Phase III Trial Recruitment 11/28/2016
ADImmune Corporation Begins Shipments To EU And Phase III Trial In Europe 11/23/2016
Galapagos (GLPG.BR) Release: Phase 3 Study With Filgotinib Initiated In Crohn's Disease 11/23/2016
AstraZeneca PLC (AZN) Catches a Break as the FDA Lifts Hold on Head And Neck Cancer Trials 11/22/2016
Onxeo Announces 9th Positive DSMB Recommendation To Continue Livatag Relive Phase III Trial In HCC 11/21/2016
Long-Term Analysis Of All 695 Patients Enrolled In NovoCure’s Phase 3 Pivotal Trial In Newly Diagnosed Glioblastoma Confirms Successful Interim Analysis Results And Demonstrates Superior Two- And Four-Year Survival Rates 11/18/2016
No Early Success for Regeneron (REGN) and Sanofi (SNY)'s Cholesterol Drug Praluent 11/17/2016
Grunenthal Has Acquired US-Based Thar Pharma To Expand Its Development Portfolio Of Treatment Options For CRPS (Complex Regional Pain Syndrome), A Serious, Disabling Orphan Disease 11/17/2016
Amgen (AMGN) and Novartis AG (NVS) Keep Lead in Migraine Drug Race on Positive Phase III Data 11/17/2016
Sanofi Genzyme (SNY) Release: Pivotal Phase 3 Trial Of NeoGAA Investigational Second-Generation Therapy For Pompe Disease To Begin In The UK 11/17/2016
NovoCure Presents Interim STELLAR Results At IASLC Suggesting Treatment With Tumor Treating Fields Plus Chemotherapy May Extend Survival Of Patients With Mesothelioma 11/17/2016
Regeneron (REGN) And Sanofi (SNY) Present Results From Phase 3 MONARCH Study Of Investigational Sarilumab At American College of Rheumatology Annual Meeting 11/16/2016
GlaxoSmithKline (GSK)'s Benlysta (Belimumab) Shows Sustained Benefits In Patients With SLE 11/16/2016
Boehringer Ingelheim Release: Updated Phase III Results Reinforce Safety And Efficacy Of Praxbind (idarucizumab) In Urgent Situations 11/16/2016
Braeburn Pharma And Camurus Announce Positive Top-Line Phase 3 Results For Long-Acting Buprenorphine (CAM2038) For Treatment Of Opioid Addiction 11/14/2016
GlaxoSmithKline (GSK) Announces Positive Results In Fourth Consecutive Pivotal Trial Of Benlysta (Belimumab) In SLE 11/14/2016
Boehringer Ingelheim Release: Patient Enrollment Completed For RE-DUAL PCI Study Assessing Dabigatran In Atrial Fibrillation Patients After PCI With Stenting 11/11/2016
Genmab A/S (GEN.CO) Announces Phase III Study Of Daratumumab In Combination With Carfilzomib In Multiple Myeloma 11/10/2016
RedHill Biopharma (RDHL) Reports Positive FDA Type B Meeting on RHB-105 For H. pylori Infection Ahead Of Confirmatory Phase III Study 11/10/2016
Intec Pharma To Sponsor Investigator Meeting For Pivotal Phase III Study Of Accordion Pill Carbidopa/Levodopa In Advanced Parkinson's Disease Patients 11/10/2016
Immunocore Presents Positive Monotherapy Data In Uveal Melanoma At The Society For Melanoma Research (SMR) 2016 Congress 11/9/2016
NovoCure Announces 38 Presentations On Tumor Treating Fields At 21st Annual Scientific Meeting Of The Society Of Neuro-Oncology 11/7/2016
Intec Pharma Announces Protocol Amendment To Phase III Study Of Accordion Pill Carbidopa/Levodopa In Advanced Parkinson's Disease Patients 11/7/2016
Sanofi (SNY) and Novartis AG (NVS) are the Worst Culprits in Reporting Clinical Trial Data, Shire (SHPG) the Best 11/4/2016
Innocoll (INNL) Slammed on Flunked Phase III Diabetic Foot Infection Trials 11/4/2016
Four Patients Suffered Serious Adverse Events While on Roche (RHHBY)'s Breakthrough Hemophilia Drug 11/3/2016
Atox Bio Announces Independent Safety Monitoring Committee Recommendation To Continue Phase 3 Study Of AB103 In Necrotizing Soft Tissue Infections 11/3/2016
RedHill Biopharma (RDHL) Provides Update On Ongoing Phase III And Phase II Studies With BEKINDA And Expected Timing Of Top-Line Results 11/3/2016
Neurim Pharmaceuticals Announces Positive Top-Line Results From Pivotal Phase III Trial Of Paediatric Prolonged-Release Melatonin (“Pedprm”) For Sleep Disturbances In Children With Autism Spectrum Disorders (ASD) 11/2/2016
Novartis AG (NVS)' Breast Cancer Contender Gets a Fast Track Ticket to the FDA, Will Take on Pfizer (PFE) 11/1/2016
AstraZeneca Canada (AZN) Release: Lynparza (Olaparib) Phase III SOLO-2 Trial Shows Significant Progression-Free Survival Benefit For Women With Ovarian Cancer 11/1/2016
Can-Fite BioPharma (CFBI) Advances Towards A Pivotal Phase III Clinical Trial In Psoriasis With Piclidenoson (CF101) Following Reaching Agreement With EMA 11/1/2016
The EMA Accepts To Assess The Marketing Authorization Application From PharmaMar For Aplidin 10/28/2016
AstraZeneca PLC (AZN) Breathes a Sigh of Relief as Lynparza Delays Ovarian Cancer Progression in Phase III Test 10/26/2016
Boehringer Ingelheim’s Adalimumab Biosimilar Candidate Shows Similar Efficacy And Safety Profile To Humira In Pivotal Phase III Study 10/26/2016
GlaxoSmithKline (GSK) Terminates Development of Losmapimod for COPD 10/26/2016
Faron Pharmaceuticals Ltd. Release: First Traumakine Phase III Patient In Japan Recruited For The Treatment Of Acute Respiratory Distress Syndrome And Update On Pan-European Phase III Traumakine Trial 10/24/2016
How 3 Huge Discoveries in 2016 are Moving Us Closer to a Breast Cancer Cure 10/24/2016
Theravance Biopharma (TBPH) And Mylan (MYL) Announce Positive Results From Two Pivotal Phase 3 Studies Of Revefenacin (TD-4208) For The Treatment Of Chronic Obstructive Pulmonary Disease (COPD) 10/20/2016
MicuRx Pharma Initiates Phase 3 Clinical Trial for MRX-I, A New Potent Oral Antibiotic Against Gram-positive Bacteria, Including MRSA 10/20/2016
PAION AG: Positive Remimazolam Phase III Colonoscopy Results Presented At The 2016 American College of Gastroenterology Annual Scientific Meeting 10/19/2016
Bayer (BAY) is Pumped Up About Its Potential Cancer Blockbuster But Investors are Skeptical 10/18/2016
Takeda (TKPYY) Showcases Continued Commitment In Hodgkin Lymphoma During 10th International Symposium On Hodgkin Lymphoma (ISHL) 10/18/2016
Shire (SHPG) Granted EU Marketing Authorization Of Onivyde, In Combination With 5-Fluorouracil (5-FU) And Leucovorin (LV),For The Treatment Of Metastatic Adenocarcinoma Of The Pancreas In Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy 10/18/2016
Ferring Pharma Receives Positive CHMP Opinion For REKOVELLE (Follitropin Delta) 10/17/2016
Starpharma Release: Enrolment Complete For Phase 3 VivaGel BV-R Program 10/13/2016
OncoGenex (OGXI) Announces Results From the Phase III ENSPIRIT Trial of Custirsen in Non-Small Cell Lung Cancer 10/13/2016
Daiichi Sankyo Announces First Patient Enrolled In Phase 3 QuANTUM-First Trial Investigating Quizartinib In Newly-Diagnosed FLT3-ITD+ Acute Myeloid Leukemia 10/11/2016
Novartis AG (NVS)-Backed Gamida Cell Nabs Breakthrough Tag for NiCord 10/11/2016
Tesaro (TSRO) Jumped on PARP Ovarian Cancer Win Vs. AstraZeneca PLC (AZN), AbbVie (ABBV) 10/11/2016
Genmab A/S (GEN.CO) Release: U.S. FDA Grants Priority Review For Daratumumab In Relapsed Multiple Myeloma 10/10/2016
Flamel Technologies (FLML) Reaches Agreement With FDA On Protocol For Phase III Pivotal Trial Of FT218 10/7/2016
RedHill Biopharma (RDHL) Provides Progress Update On RHB-104 Phase III Crohn’s Disease Program And Introduces Option For Early Stop For Success In Q2/2017 10/6/2016
Hanyang University Guri Hospital: CIK Treatment Extends Progression-free Survival Of Glioblastoma Patients By 1.5 Times 10/5/2016
Chugai Pharma's ACTEMRA/RoACTEMRA Receives Breakthrough Therapy Designation From U.S. FDA For Giant Cell Arteritis 10/5/2016
Chugai Pharma's Alecensa Receives Breakthrough Therapy Designation From FDA For First-Line Treatment Of ALK Positive Non-Small Cell Lung Cancer 10/4/2016
infirst Healthcare Announces Positive Phase III Results Of Its Lipid Formulated Ibuprofen Capsules (BC1054) 10/4/2016
MorphoSys AG Announces That Its Licensee Janssen R&D Reports Positive Results From A Phase 3 Study Of Guselkumab In Plaque Psoriasis 10/4/2016
Regeneron (REGN), Sanofi (SNY) Tout Phase III Dupixent Data 10/3/2016
Bay Area Dermira (DERM)'s CImzia Meets Co-Primary Endpoints in Key Phase III Study 10/3/2016
FDA Slaps Clinical Hold on Alcobra (ADHD)'s Late Stage ADHD Study 9/29/2016
Moberg Pharma AB (Formerly known as Moberg Derma) Begins Patient Enrollment In North America And Europe In Two Phase 3 Studies Of MOB-015 In Onychomycosis 9/28/2016
Galapagos (GLPG.BR) Release: Successful Completion Of Regulatory Consultations To Progress Filgotinib To Phase 3 In Inflammatory Bowel Disease 9/28/2016
Jazz Pharma (JAZZ) Announces That Patient Enrollment Is Complete For The Phase 3 Studies Of JZP-110 Evaluating Excessive Sleepiness In Obstructive Sleep Apnea 9/27/2016
GW Pharma (GWPH)'s Cannabis-Derived Drug Successful in Third Late-Stage Epilepsy Study 9/26/2016
This Biotech Has the Upper Hand Over Allergan (AGN) and Gilead (GILD) in the Heated Nash Battle 9/23/2016
Armed With Fresh Phase III Data, Novartis AG (NVS) Eyes First-Line Use for Lung Cancer Drug Zykadia 9/23/2016
H. Lundbeck A/S (LUN.CO)'s Phase III Data Crushes Hope for Alzheimer’s Once Again 9/23/2016
Teva (TEVA) Announces Positive Top-Line Data From Second Phase III Study Of SD-809 In Tardive Dyskinesia (TD) 9/22/2016
The Drugmaker That Could Knock Gilead (GILD) Off Its HIV Throne 9/20/2016
FDA Takes Back Special Protocol Assessment for Active Biotech (BTPC)'s Laquinimod 9/19/2016
Amgen (AMGN), UCB Group (UCBJF.PK)'s Romosozumab Showed Significant Results in Phase III Study 9/19/2016
Novo Nordisk A/S (NVO)'s New Diabetes Med Semaglutide Slashes Heart Disease Risk 9/16/2016
Treatment Effects Maintained Over Six Years In Patients With Relapsing Remitting Multiple Sclerosis Who Received Sanofi Genzyme (SNY)’s Lemtrada (Alemtuzumab) In Clinical Trials 9/16/2016
GlaxoSmithKline (GSK)'s Experimental Shingles Vaccine 90% Effective in People Over Age 70 9/15/2016
Innovent Biologics Starts China Trials of Two Biologic Drug Candidates 9/15/2016
GenSight Biologics Receives Approval To Include Teenage Patients In RESCUE And REVERSE Phase III Trials With GS010 In Leber’s Hereditary Optic Neuropathy 9/8/2016
Boehringer Ingelheim Release: New Analysis Showed Dose Adjustment Of Giotrif (Afatinib) Improved Tolerability Without An Apparent Impact On Efficacy In Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer 9/8/2016
Theravance Biopharma (TBPH) Touts Significant Data from Pivotal Phase III FULFIL Study 9/8/2016
Takeda (TKPYY) Initiates Global Phase III Clinical Trial (TIDES) Of Dengue Vaccine Candidate (TAK-003) 9/7/2016
AstraZeneca PLC (AZN)'s Asthma Candidate Does Well in Final Late-Stage Test 9/6/2016
vasopharm BIOTECH GmbH Announces Enrollment Of First Patient In Phase III Traumatic Brain Injury (TBI) Trial 9/6/2016
Faron Pharmaceuticals Ltd. Release: Interim Results 2016: Progress Continued In Traumakine Phase III And With Clevegen Indications Extended 9/6/2016
Boehringer Ingelheim Release: New Data: Spiolto Respimat Significantly Improves Exercise Capacity In People With COPD 9/6/2016
GlaxoSmithKline (GSK) Presents Positive Results From Phase III Fulfil Study Of Closed Triple Combination Therapy Ff/Umec/Vi Versus Symbicort Turbohaler In COPD At ERS International Congress 9/6/2016
Boehringer Ingelheim Release: Tiotropium Respimat Improved Lung Function In Children With Asthma Aged 6-17 And Is Well-Tolerated Compared To Placebo In Children Aged 1-171-5 9/6/2016
MorphoSys AG Initiates Phase 2/3 Trial Of CD19 Antibody MOR208 Plus Bendamustine In Patients With Relapsed Or Refractory DLBCL 9/6/2016
Vectura (VEC.L)'s Asthma Med Flutiform Flunks Final Late-Stage Study 8/30/2016
Adocia's Foot Ulcer Med Flunks Phase III Test 8/26/2016
NeuroDerm (NDRM) Initiates Patient Enrollment In A Phase III Trial Of ND0612L For The Treatment Of Parkinson’s Disease 8/25/2016
Galapagos (GLPG.BR) Release: Finch Filgotinib Phase 3 Program Initiated In Rheumatoid Arthritis 8/23/2016
Mezzion (140410.KQ) And NHLBI Initiate Enrollment In A Pivotal Phase 3 Clinical Trial Of Udenafil In Adolescents With Fontan Surgical Palliation - An Orphan Drug Indication 8/22/2016
Auris Med (EARS)'s Tinnitus Drug Misses Main Goals in Study; Shares Sink 8/18/2016
Indivior Shows Off Late-Stage Opiod Addiction Trial Data 8/17/2016
Vertex (VRTX) Dumps Phase III Cystic Fibrosis Study 8/17/2016
Ascendis Pharma A/S Announces R&D Update To Review Expanded Pipeline And Long-Term Strategic Outlook 8/16/2016
ViiV Healthcare Launches Phase III Programme Evaluating A Two-Drug Regimen Combining Dolutegravir And Lamivudine For HIV-1 Treatment 8/16/2016
Axovant (AXON) Announces Expansion Of Dementia Pipeline And Reports Financial Results For The First Fiscal Quarter Ended June 30, 2016 8/16/2016
OncoGenex (OGXI) Hires Advisor, Seeks Strategic Alternatives After Cancer Drug Custirsen Study Fails 8/16/2016
Acacia Pharma Announces Positive Results From A Pivotal Phase 3 Trial Of BAREMSIS For The Treatment Of Post-Operative Nausea & Vomiting 8/12/2016
Resverlogix (RVX.TO) Announces Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study Of Apabetalone (RVX-208) 8/11/2016
Ascendis Pharma A/S Initiates Phase 3 Registration Trial For TransCon Growth Hormone In Children With Growth Hormone Deficiency 8/11/2016
PharmaMar Announces The IDMC´s Response On The CORAIL Trial Using PM1183 8/11/2016
Eisai Company (ESALY.PK) Release: U.S. FDA Confirms Sufficient Data To Advance Investigational Bace Inhibitor E2609 For Treatment Of Early Alzheimer’s Disease To PHASE III 8/10/2016
ThromboGenics NV (TBGNF) 2-Year OASIS Study Results Published In Ophthalmology, Journal Of The American Academy Of Ophthalmology (AAO) 8/8/2016
Allergan (AGN), Gedeon Richter (RIG2.F) Face Setback in Cariprazine Antidepressant Trial 8/5/2016
Amarin (AMRN) And FDA Reaffirm Concurrence On REDUCE-IT Through Special Protocol Assessment Agreement Amendment 8/4/2016
FDA Bestows Novartis AG (NVS)'s Breast Cancer Pill With Breakthrough Tag 8/3/2016
Sanofi (SNY) And Regeneron (REGN) Announce EMA Acceptance For Review Of Marketing Authorisation Application For Sarilumab 8/1/2016
Eisai Company (ESALY.PK) Presents Results Of Additional Analysis Of Phase III Study Of Anticancer Agent Halaven At 14th JSMO Annual Meeting Plenary Session 8/1/2016
Takeda (TKPYY), Seattle Genetics (SGEN) Show Off Significant Phase III ALCANZA Data for T-Cell Lymphoma 8/1/2016
First Patient Enrolled In Mallinckrodt (MNK) Phase 3 Terlipressin Trial 7/29/2016
AstraZeneca PLC (AZN) Kills Six Pipeline Programs 7/28/2016
TauRx Pharma's Much-Watched Alzheimer's Drug Flops in Trial 7/27/2016
Boehringer Ingelheim Halts Two Phase III Trials for Lung Cancer Drug Gilotrif 7/27/2016
Astellas (ALPMY) And FibroGen (FGEN) Announce First Patient Treated In Phase III Studies And Positive Phase II Results Of Roxadustat In Patients With Chronic Kidney Disease In Japan 7/26/2016
Shire (SHPG) Release: ONIVYDE Receives Positive CHMP Opinion For Treatment Of Patients With Metastatic Adenocarcinoma Of The Pancreas Who Have Progressed Following Gemcitabine Based Therapy 7/25/2016
Alcobra (ADHD) Granted European Orphan Drug Designation For Metadoxine In Fragile X Syndrome 7/19/2016
ViiV Healthcare Release: ARIA Study Shows Superior Efficacy Of Triumeq For Treatment-Naïve Women Living With HIV 7/18/2016
Biogen (BIIB) And Sobi To Showcase Long-Term Efficacy And Safety Data From Extended Half-Life Hemophilia Therapies At World Federation Of Hemophilia 2016 World Congress 7/18/2016
Alizé Pharma To Present Results From AZP-531 Phase II Trial In Prader-Willi Syndrome At Two Upcoming Scientific Conferences 7/18/2016
Nuvo Pharmaceuticals Inc. Announces Pennsaid 2% Phase 3 Trial To Support Regulatory Approvals In The E.U., Canada And Australia 7/13/2016
Cipher Pharma (DND.TO) Announces Ozenoxacin Accepted For Review By Health Canada 7/12/2016
Novo Nordisk A/S (NVO) To Present 28 Abstracts At The World Federation Of Hemophilia World Congress In Orlando 7/12/2016
ENGOT And Tesaro (TSRO) Partnership Generates Positive Data From ENGOT-OV16/NOVA Phase 3 Trial 7/11/2016
Bausch & Lomb And Nicox Announce The Publication Of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results In American Journal Of Ophthalmology 7/6/2016
Merck KGaA (MKGAF.PK), Darmstadt, Germany, And Pfizer (PFE) Initiate Phase III Trial To Evaluate Avelumab As First-Line Treatment For Ovarian Cancer 7/6/2016
Merck & Co. (MRK) And Pfizer (PFE) Initiate Phase III Trial To Evaluate Avelumab As First-Line Treatment For Ovarian Cancer 7/6/2016
Teva (TEVA) And The Huntington Study Group Announce Publication Of Pivotal Phase III Data On Deutetrabenazine (SD-809) In Huntington Disease From First-HD Trial In JAMA 7/5/2016
Allergan (AGN) Receives Positive Opinion Through European Decentralised Procedure For BELKYRA (Deoxycholic Acid) For Patients With Submental Fullness 7/1/2016
Mesoblast (MSB.AX) Plans to Reduce FY17 Cash Burn to Fund Clinical Operations and Phase III Heart Failure Trial 7/1/2016
BeyondSpring Pharmaceuticals's Global Phase III Non-Small Cell Lung Cancer Clinical Trial For Plinabulin Launches In China 6/28/2016
Celyad’s CHART-1 Phase III Shows No Significant Difference on Primary Endpoint 6/28/2016
Phase III Data Show Bayer (BAY)'s Stivarga (Regorafenib) Improved Overall Survival In Previously Treated Patients With Unresectable Liver Cancer 6/28/2016
GW Pharma (GWPH)’s Epidiolex Meets Primary Endpoint in Phase III 6/27/2016
AnGes Terminates Phase III HGF Plasmid, Starts New Plan 6/27/2016
Roche (RHHBY) CEO 'Sleeping Much Better' Following Positive News About Three New Drugs 6/23/2016
Innocoll (INNL) Announces The Completion Of Enrollment In Two Pivotal Phase III Clinical Trials Of COGENZIA For The Treatment Of Diabetic Foot Infections 6/23/2016
Concordia Healthcare Announces PDT With Photofrin Data And Provides Corporate Update 6/20/2016
GlaxoSmithKline (GSK)'s Lung Drug Passes Phase III Test 6/20/2016
Circassia (CIR.L) Stock Crashes as Allergy Drug Flunks Crucial Phase III Study 6/20/2016
Can-Fite BioPharma (CFBI) Reports New Data Showing Its Psoriasis Drug May Offer Efficacy Similar To Industry Leading Biologics Without Harmful Side Effects 6/16/2016
IBSA Release: Prescription Chondroitin Sulphate Is As Efficacious As Celecoxib And Better Than Placebo In Knee Osteoarthritis 6/14/2016
Novo Nordisk Canada Inc. (NVO) Release: Faster-Acting Insulin Aspart Showed A Statistically Significant Reduction In Hba(1c) In Type 1 Diabetes And A Comparable HbA(1c) Reduction In Type 2 Diabetes Versus NovoRapid (Insulin Aspart) 6/14/2016
Sanofi (SNY)'s New Diabetes Combo Nails Late-Stage Goals 6/13/2016
REPEAT/Janssen-Cilag International NV (JNJ)’s EPREX (Epoetin Alfa) Demonstrates Effectiveness As A Treatment For Anaemia In Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndromes 6/13/2016
Janssen-Cilag International NV (JNJ)’s EPREX (Epoetin Alfa) Demonstrates Effectiveness As A Treatment For Anaemia In Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndromes 6/13/2016
Janssen-Cilag International NV (JNJ) Release: Daratumumab Significantly Extended Progression-Free Survival In Combination With Lenalidomide And Dexamethasone In Patients With Multiple Myeloma 6/10/2016
Bristol-Myers Squibb Canada (BMY) Release: Canada's Health Technology Assessment Agency Gives Positive Recommendation For OPDIVO To Treat Non-Small Cell Lung Cancer 6/9/2016
GlaxoSmithKline (GSK), Johnson & Johnson (JNJ)'s Rheumatoid Arthritis Drug Meets Goals in Large Late-Stage Study 6/8/2016
New Janssen R&D Phase 3 Data In Patients With Moderately To Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression And Improved Signs And Symptoms Of Disease 6/8/2016
Samsung Bioepis Announces New Data On Three Anti-TNF--a Biosimilar Molecules At The Annual European Congress On Rheumatology (EULAR 2016) 6/8/2016
Can-Fite BioPharma (CFBI) Submits Psoriasis Phase III Protocol And Registration Plan To European Medicines Agency For Piclidenoson (CF101) 6/7/2016
ASCO2016: Mylan (MYL)-BioCon (BIOCON.NS)'s Biosimilar Cancer Drug Comparable to Roche (RHHBY)'s Herceptin 6/6/2016
ASCO2016: SELLAS Life Sciences Group Announces Exciting Results For Galinpepimut-S, The Company's WT1 Vaccine, In Patients With Acute Myeloid Leukemia (AML) And Malignant Pleural Mesothelioma (MPM), As Presented At The 2016 ASCO Annual Meeting 6/6/2016
Merck & Co. (MRK) Partners With Array BioPharma (ARRY) And Pierre Fabre To Initiate BRAF-Mutant CRC Phase III Trial 6/6/2016
ASCO2016: OBI Pharma (SHPG) Presents Data For Novel Investigational OBI-822/OBI-821 In Patients With Metastatic Breast Cancer At The 2016 American Society Of Clinical Oncology Annual Meeting 6/6/2016
ASCO2016: Janssen Pharmaceutical Release: Daratumumab (DARZALEX) Combination Therapy Significantly Extended Progression-Free Survival In Previously Treated Patients With Multiple Myeloma 6/6/2016
Theravance Biopharma (TBPH) Completes Enrollment In All Three Phase 3 Clinical Studies Of Revefenacin (TD-4208) For Treatment Of Chronic Obstructive Pulmonary Disease (COPD) 6/2/2016
Astellas (ALPMY) And Medivation (MDVN) Initiate Phase III Trial Of Enzalutamide In Patients With Triple-Negative Breast Cancer 6/2/2016
Boehringer Ingelheim Launches Ambitious ELUXA Trial Programme To Broadly Investigate Promising Lung Cancer Compound Olmutinib 6/2/2016
Nektar Therapeutics (NKTR), DAIICHI SANKYO EUROPE GmbH Strike $80 Million+ ONZEALD Pact 6/1/2016
Can-Fite BioPharma (CFBI) Reaches Agreement With European Medicines Agency On Pivotal Phase III Clinical Trial With Piclidenoson (CF101) In Rheumatoid Arthritis 6/1/2016
PharmaEngine, Inc. Announces Initiation Of Global Pivotal Trial Of PEP503 (NBTXR3) In Soft Tissue Sarcoma In Asia Pacific Region 6/1/2016
Helsinn Group To Present At ASCO Pooled Follow Up Efficacy Data Analysis From Two Phase III Studies For Anamorelin In Cachectic Patients With Non-Small Cell Lung Cancer (NSCLC) 6/1/2016
Daiichi Sankyo, Inc. (DSNKY) Not Proceed With Lung Cancer Study 5/31/2016
Novartis AG (NVS) Trial Stopped Early on Positive Data, Gets Ready to Take on Pfizer (PFE)'s Ibrance 5/31/2016
Innocoll (INNL)'s Painkiller Passes Final Phase III Tests, Heads for 2017 Launch 5/25/2016
SELLAS Life Sciences Group Announces Upcoming Presentation Of Phase 2 Clinical Results For WT1 Cancer Vaccine At The 2016 ASCO Annual Meeting 5/24/2016
Shionogi Release: Two Naldemedine Phase III Studies Show Consistent Improvement Of Opioid-Induced Constipation 5/24/2016
Alkermes (ALKS) To Present Data On ALKS 5461 At Upcoming American Society Of Clinical Psychopharmacology Annual Meeting 5/24/2016
Norgine Release: New Positive Phase III Study For NER1006 - The First 1 Litre PEG-Based Bowel Preparation 5/24/2016
After Initial Miss, GlaxoSmithKline (GSK)'s Pioneering Lung Study Shows Positive Results 5/24/2016
FDA Questions Study Findings, Practicality of Novo Nordisk A/S (NVO)'s Diabetes Drug Ideglira 5/23/2016
Genmab A/S (GEN.CO) Announces Positive Topline Result In Phase III POLLUX Study Of Daratumumab In Relapsed Or Refractory Multiple Myeloma 5/19/2016
AstraZeneca PLC (AZN)'s Gastric Cancer Drug Lynparza Flunks Phase III Test 5/18/2016
AstraZeneca PLC (AZN)'s Asthma Drug Hits Phase III Goal, Predicted to Reach Market in 2017 5/18/2016
European Scleroderma Trial Investigating Cytori Therapeutics (CYTX) Cell Therapy To Be Presented In Japan 5/17/2016
SillaJen Announces Commercial Manufacturing Agreement With ABL Europe For Lead Oncolytic Virus, Pexa-Vec 5/16/2016
Theravance Biopharma (TBPH) Release: New Data Analyses From Phase 3 ATTAIN Trials Support VIBATIV (Telavancin) As A Treatment For Staphylococcus Aureus HABP/VABP, Including Cases Caused By MRSA 5/16/2016
OncoGenex (OGXI) Reports Financial Results For First Quarter 2016 5/13/2016
Hutchison China MediTech (Chi-Med) Completes Enrollment Of 416 Patients In Pivotal Phase III FRESCO Trial With Fruquintinib in Colorectal Cancer 5/13/2016
Theravance Biopharma (TBPH) To Present New Data Analyses From Phase 3 ATTAIN Trials Of VIBATIV (Telavancin) In Treatment Of HABP/VABP At American Thoracic Society 2016 International Conference 5/12/2016
Santen Europe Release: Vekacia (Ciclosporin 1mg/mL Eye Drops) Pivotal Trial Meets Primary And Key Secondary Endpoints 5/11/2016
Allergan (AGN) And Gedeon Richter (RIG2.F) Announce Positive Phase III Results For Ulipristal Acetate 5 And 10 Mg In The Treatment Of Uterine Fibroids 5/9/2016
DelMar Pharma Announces $5.6 Million Private Placement Of Preferred Shares 5/5/2016



//-->